AtriCure (NASDAQ:ATRC) Insider Sells 8,404 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 8,404 shares of AtriCure stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the completion of the transaction, the insider owned 134,341 shares of the company’s stock, valued at $8,732,165. This represents a 5.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 23rd, Salvatore Privitera sold 4,519 shares of AtriCure stock. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00.
• On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00.
• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Stock Down 6.5%

Shares of ATRC traded down $4.27 during midday trading on Thursday, reaching $61.26. The stock had a trading volume of 978,420 shares, compared to its average volume of 875,183. The company has a market cap of $3.12 billion, a price-to-earnings ratio of 204.21 and a beta of 1.23. The company’s fifty day simple moving average is $56.36 and its two-hundred day simple moving average is $38.52. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $66.02. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.23. AtriCure had a return on equity of 4.08% and a net margin of 2.52%. The firm had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. Equities research analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of estimates, and revenue of $154.45 million topped forecasts of $151.05 million. AtriCure beats Q3 earnings and revenue estimates
• Positive Sentiment: AtriCure raised its 2026 revenue outlook to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. It also aims to complete BoxX-NoAF enrollment by year-end. 2026 EBITDA outlook and enrollment target
• Positive Sentiment: Analysts raised targets following the results: Piper Sandler and Needham lifted theirs to $70, while Canaccord raised its target to $67 and maintained a Buy rating. Analysts raise forecasts after Q3 results
• Neutral Sentiment: JPMorgan raised its target to $62 but kept a Neutral rating, signaling more limited expected upside from its assessment. Analyst forecast updates
• Negative Sentiment: Despite the upbeat results and guidance, investors may be weighing whether ATRC is fully valued after its substantial run-up. Its elevated valuation could make the shares vulnerable to profit-taking and help explain the pullback. Is AtriCure fully valued after strong results and raised guidance?

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ATRC shares. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Wednesday, October 21st. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. UBS Group cut shares of AtriCure from a “buy” rating to a “sell” rating in a report on Wednesday, October 21st. Finally, Citizens Jmp lifted their price target on shares of AtriCure from $52.00 to $68.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 21st. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, AtriCure has an average rating of “Hold” and a consensus target price of $61.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of AtriCure during the second quarter worth about $125,198,000. Wellington Management Group LLP grew its stake in shares of AtriCure by 3.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock valued at $97,807,000 after purchasing an additional 113,048 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of AtriCure by 8.2% during the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares during the period. Bank of America Corp DE acquired a new stake in shares of AtriCure during the second quarter worth $24,465,000. Finally, Grandeur Peak Global Advisors LLC purchased a new position in AtriCure in the 2nd quarter valued at $16,435,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.